This is an application for a new Conte Center for Schizophrenia Research based at the New York University School of Medicine (NYUSoM) and the affiliated Nathan Kline Institute for Psychiatric Research (NKI). Schizophrenia (SZ) is associated with sensory processing deficits that represent a core, but understudied, connponent of the disorder. In the auditory system, patients show deficits in basic processes such as tone matching and auditory mismatch negativity (MMN) generation. In the visual system, patients show deficits in processes such as contrast gain and integration that contribute to higher order impairments in processes such as object recognition and face recognition. Sensory deficits may relate specifically to impairments in Nmethyl- D-aspartate (NMDA) receptor-mediated neurotransmission, and are especially amenable to translational investigation using human and animal models. The Center consists of 6 projects and 3 cores, which build from pre-existing collaborations among Center investigators. Projects 1, 2 and 4 are based at NKI/NYSoM and utilize human (Javitt) and primate (Schroeder) neurophysiological, and human postmortem/laser capture microscopy/gene array (Ginsberg/Smiley) approaches to the study of sensory cortical dysfunction and impaired functional connectivity in SZ. Project 3 (Hlllyard) is based at UCSD and investigates modulatory processes underlying normal visual function. Project 5 (Cornblatt) is based at Zucker Hillside Hospital and investigates sensory processing dysfunction within the SZ prodrome. Finally, Project 6 (Weiser) is based at Sheba Hospital/Tel Aviv University and evaluates effectiveness of sarcosine (N-methylglycine), a naturally occurring NMDA agonist not currently available in the US. Cores are devoted to administration (Javitt), patient recruitment/assessment (Butler) and data management/biostatistics (Robinson/Petkova). Although traditional models of SZ focus on dopamine, more recent models focus on underlying glutamatergic dysfunction, and have received support from neurogenetic, imaging, and treatment studies, as well as challenge studies with putative NMDA antagonists. The overall goal of the Center is to develop new assessment and intervention approaches for schizophrenia based upon glutamatergic models.
Schizophrenia is a major mental disorder that affects approximately 1% of the population worldwide. Current medications significantly control symptoms of schizophrenia, but are relatively ineffective in treating underlying neurocognitive deficits or in modifying neuro-physiological markers of underlying brain dysfunction. The present Center focuses on alternative neurochemical conceptualizations of schizophrenia, and development of novel models and methods for brain assessment and intervention.
|Corcoran, Cheryl M; Stoops, Anastasia; Lee, Migyung et al. (2018) Developmental trajectory of mismatch negativity and visual event-related potentials in healthy controls: Implications for neurodevelopmental vs. neurodegenerative models of schizophrenia. Schizophr Res 191:101-108|
|Lee, Migyung; Balla, Andrea; Sershen, Henry et al. (2018) Rodent Mismatch Negativity/theta Neuro-Oscillatory Response as a Translational Neurophysiological Biomarker for N-Methyl-D-Aspartate Receptor-Based New Treatment Development in Schizophrenia. Neuropsychopharmacology 43:571-582|
|Brucato, Gary; Appelbaum, Paul S; Masucci, Michael D et al. (2018) Prevalence and phenomenology of violent ideation and behavior among 200 young people at clinical high-risk for psychosis: an emerging model of violence and psychotic illness. Neuropsychopharmacology :|
|Kantrowitz, Joshua T; Epstein, Michael L; Lee, Migyung et al. (2018) Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: Correlation with symptoms. Schizophr Res 191:70-79|
|Poe, Sarah-Lucy; Brucato, Gary; Bruno, Nicolina et al. (2017) Sleep disturbances in individuals at clinical high risk for psychosis. Psychiatry Res 249:240-243|
|Zhao, Jizheng; Li, Mintong; Zhang, Yi et al. (2017) Intrinsic brain subsystem associated with dietary restraint, disinhibition and hunger: an fMRI study. Brain Imaging Behav 11:264-277|
|Kantrowitz, Joshua T; Nolan, Karen A; Epstein, Michael L et al. (2017) Neurophysiological Effects of Bitopertin in Schizophrenia. J Clin Psychopharmacol 37:447-451|
|Lee, M; Sehatpour, P; Hoptman, M J et al. (2017) Neural mechanisms of mismatch negativity dysfunction in schizophrenia. Mol Psychiatry 22:1585-1593|
|Potvin, Olivier; Dieumegarde, Louis; Duchesne, Simon et al. (2017) Freesurfer cortical normative data for adults using Desikan-Killiany-Tourville and ex vivo protocols. Neuroimage 156:43-64|
|Brucato, G; Masucci, M D; Arndt, L Y et al. (2017) Baseline demographics, clinical features and predictors of conversion among 200 individuals in a longitudinal prospective psychosis-risk cohort. Psychol Med 47:1923-1935|
Showing the most recent 10 out of 96 publications